Patient and Physician Perceptions of Drug Safety Information for Sleep Aids: A Qualitative Study

Overview

Journal Drug Saf

Specialties Pharmacology
Toxicology

Date 2017 Mar 2

PMID 28247279

Citations 8

Authors

Aaron S Kesselheim

Sarah A McGraw

Sara Z Dejene

Paula Rausch

Gerald J Dal Pan

Brian M Lappin

Esther H Zhou

Jerry Avorn

Eric G Campbell

Affiliations

Soon will be listed here.

Abstract

Introduction: The US Food and Drug Administration uses drug safety communications (DSCs) to release emerging information regarding post-market safety issues, but it is unclear the extent of awareness by patients and providers of these communications and their specific recommendations.

Objective: We conducted semi-structured interviews with patients and physicians to evaluate their awareness and understanding of emerging drug safety information related to two sleep aids: zolpidem or eszopiclone.

Methods: We conducted interviews with 40 patients and ten physicians recruited from a combination of insurer claims databases and online sources. We evaluated (1) sources of drug safety information; (2) discussions between patients and physicians about the two medications; (3) their knowledge of the DSC; and (4) preferences for learning about future drug safety information. Interviews were transcribed and analyzed thematically.

Results: Patients cited their physicians, pharmacy inserts, and the Internet as sources of drug safety information. Physicians often referred to medical journals and online medical sources. Most patients reported being aware of information contained in the DSC summaries they were read. Almost all patients and physicians reported discussing side effects during patient-provider conversations, but almost no patients mentioned that physicians had communicated with them key messaging from the DSCs at issue: the risk of next-morning impairment with zolpidem and the lower recommended initial dose for women.

Conclusions: Some risks of medications are effectively communicated to patients and physicians; however, there is still a noticeable gap between information issued by the Food and Drug Administration and patient and physician awareness of this knowledge, as well as patients' decisions to act on this information. Disseminators of emerging drug safety information should explore ways of providing user-friendly resources to patients and healthcare professionals that can update them on new risks in a timely manner.

Citing Articles

Challenges in the Implementation of EU Risk Minimisation Measures for Medicinal Products in Clinical Practice Guidelines: Mixed Methods Multi-Case Study.

Mollebaek M, Gardarsdottir H, Bikou A, Kodric A, Silva A, Andersen A Drug Saf. 2024; 48(2):161-177.

PMID: 39570566 PMC: 11785605. DOI: 10.1007/s40264-024-01487-5.

Communicating for the Safe Use of Medicines: Progress and Directions for the 2020s Promoted by the Special Interest Group of the International Society of Pharmacovigilance.

Bahri P, Bowring G, Edwards B, Anton C, Aronson J, Caro-Rojas A Drug Saf. 2023; 46(6):517-532.

PMID: 37219785 PMC: 10203670. DOI: 10.1007/s40264-023-01285-5.

Physicians' use of and preferences for FDA-approved prescribing information.

Sullivan H, Squire C, Aikin K, Tzeng J, Ferriola-Bruckenstein K, Brodsky E Res Social Adm Pharm. 2021; 18(6):3027-3037.

PMID: 34364803 PMC: 8803992. DOI: 10.1016/j.sapharm.2021.07.028.

Personal Formularies of Primary Care Physicians Across 4 Health Care Systems.

Galanter W, Eguale T, Gellad W, Lambert B, Mirica M, Cashy J JAMA Netw Open. 2021; 4(7):e2117038.

PMID: 34264328 PMC: 8283562. DOI: 10.1001/jamanetworkopen.2021.17038.

Interrupted Time Series Analysis of Changes in Zolpidem Use Due to Media Broadcasts.

Yang B, Heo K, Yu Y, Yeom G, Choi H, Lee J Int J Environ Res Public Health. 2021; 18(10).

PMID: 34065935 PMC: 8150593. DOI: 10.3390/ijerph18105114.

References

Hayden C, Neame R, Tarrant C . Patients' adherence-related beliefs about methotrexate: a qualitative study of the role of written patient information. BMJ Open. 2015; 5(5):e006918. PMC: 4442177. DOI: 10.1136/bmjopen-2014-006918. View

Prosser H, Almond S, Walley T . Influences on GPs' decision to prescribe new drugs-the importance of who says what. Fam Pract. 2003; 20(1):61-8. DOI: 10.1093/fampra/20.1.61. View

Richardson L, Lewis C, Casey-Goldstein M, McCauley E, Katon W . Pediatric primary care providers and adolescent depression: a qualitative study of barriers to treatment and the effect of the black box warning. J Adolesc Health. 2007; 40(5):433-9. DOI: 10.1016/j.jadohealth.2006.12.006. View

Fischhoff B . Risk perception and communication unplugged: twenty years of process. Risk Anal. 1995; 15(2):137-45. DOI: 10.1111/j.1539-6924.1995.tb00308.x. View

Conrardy M, Lank P, Cameron K, McConnell R, Chevrier A, Sears J . Emergency Department Patient Perspectives on the Risk of Addiction to Prescription Opioids. Pain Med. 2015; 17(1):114-21. DOI: 10.1111/pme.12862. View

Dusetzina S, Higashi A, Ray Dorsey E, Conti R, Huskamp H, Zhu S . Impact of FDA drug risk communications on health care utilization and health behaviors: a systematic review. Med Care. 2012; 50(6):466-78. PMC: 3342472. DOI: 10.1097/MLR.0b013e318245a160. View

Kalkan A, Roback K, Hallert E, Carlsson P . Factors influencing rheumatologists' prescription of biological treatment in rheumatoid arthritis: an interview study. Implement Sci. 2014; 9:153. PMC: 4200139. DOI: 10.1186/s13012-014-0153-5. View

Kesselheim A, Campbell E, Schneeweiss S, Rausch P, Lappin B, Zhou E . Methodological approaches to evaluate the impact of FDA drug safety communications. Drug Saf. 2015; 38(6):565-75. DOI: 10.1007/s40264-015-0291-y. View

Svarstad B, Mount J, Tabak E . Expert and consumer evaluation of patient medication leaflets provided in U.S. pharmacies. J Am Pharm Assoc (2003). 2005; 45(4):443-51. DOI: 10.1331/1544345054475586. View

10.

Knox C, Hampp C, Willy M, Winterstein A, Dal Pan G . Patient understanding of drug risks: an evaluation of medication guide assessments. Pharmacoepidemiol Drug Saf. 2015; 24(5):518-25. PMC: 4733651. DOI: 10.1002/pds.3762. View

11.

Dal Pan G . Communicating the risks of medicines: time to move forward. Med Care. 2012; 50(6):463-5. DOI: 10.1097/MLR.0b013e31825852f0. View

12.

Piening S, Haaijer-Ruskamp F, de Vries J, van der Elst M, de Graeff P, Straus S . Impact of safety-related regulatory action on clinical practice: a systematic review. Drug Saf. 2012; 35(5):373-85. DOI: 10.2165/11599100-000000000-00000. View

13.

Hsieh H, Shannon S . Three approaches to qualitative content analysis. Qual Health Res. 2005; 15(9):1277-88. DOI: 10.1177/1049732305276687. View

14.

Teutsch C . Patient-doctor communication. Med Clin North Am. 2003; 87(5):1115-45. DOI: 10.1016/s0025-7125(03)00066-x. View

15.

Seamark D, Seamark C, Greaves C, Blake S . GPs prescribing of strong opioid drugs for patients with chronic non-cancer pain: a qualitative study. Br J Gen Pract. 2013; 63(617):e821-8. PMC: 3839391. DOI: 10.3399/bjgp13X675403. View

16.

Winterstein A, Linden S, Lee A, Fernandez E, Kimberlin C . Evaluation of consumer medication information dispensed in retail pharmacies. Arch Intern Med. 2010; 170(15):1317-24. DOI: 10.1001/archinternmed.2010.263. View

17.

Bertisch S, Herzig S, Winkelman J, Buettner C . National use of prescription medications for insomnia: NHANES 1999-2010. Sleep. 2014; 37(2):343-9. PMC: 3900622. DOI: 10.5665/sleep.3410. View

18.

Curry L, Nembhard I, Bradley E . Qualitative and mixed methods provide unique contributions to outcomes research. Circulation. 2009; 119(10):1442-52. DOI: 10.1161/CIRCULATIONAHA.107.742775. View

19.

Koppen L, Phillips J, Papageorgiou R . Analysis of reference sources used in drug-related Wikipedia articles. J Med Libr Assoc. 2015; 103(3):140-4. PMC: 4511054. DOI: 10.3163/1536-5050.103.3.007. View

20.

Dal Pan G . Commentary on "The effectiveness of varenicline medication guide for conveying safety information to patients: a REMS assessment survey" by Enger et al. Pharmacoepidemiol Drug Saf. 2013; 22(7):716-8. DOI: 10.1002/pds.3450. View